Tilray Pops 50% as Marijuana Clinical Trials Power Growth
*By Carlo Versano*
As cannabis companies like Canopy Growth and Aurora align themselves with consumer beverage brands, Tilray ー the pot stock that's up a cool 600 percent since its July IPO and has added more than $7 billion to its market cap just on Wednesday ー is taking a different tack.
The Canada-based company is making a "really strong push" into clinical trials for medical marijuana, said Bethany Gomez, director of research for consulting firm Brightfield Group.
That strategy, illustrated by Tuesday's announcement that Tilray got DEA clearance to import cannabis to the U.S. for a University of California San Diego research study, appears to be paying off.
Tilray shares were up by as much as 50 percent Wednesday ー adding to gains of nearly 30 percent the day before ー giving the company a market cap of more than $21 billion, above that of much older, established companies like Best Buy and CBS. The stock, which debuted at $17 a share two months ago, now trades over $200.
"They're aligning themselves very well in a lot of key areas," Gomez said.
Tilray is essentially making a bet that it can get into a "preferred stance" to negotiate with international governments that are beginning to grant small numbers of licenses for medical marijuana research, Gomez said.
By partnering with research facilities like the one at UCSD, Tilray has a "first mover advantage" when those licenses are given out, she said.
But whether optimism on that front justifies the stock's price gains is up for debate. On Wednesday morning Citron Research, known for making bearish bets on stocks, [tweeted](https://twitter.com/CitronResearch/status/1042395769372909568) that Tilray's jump was "beyond comprehension." The firm said, "We are short and will hold a manageable position until rationality sets in."
Tilray is just one of several marijuana stocks that are experiencing highs. On average, the group is up about 30 percent since August, [according to IHS Markit](https://www.nytimes.com/2018/09/17/business/dealbook/shorting-cannabis-stocks-costly.html).
But it's a long game, Gomez said. "There's going to be ups, and there's going to be downs."
For full interview [click here](https://cheddar.com/videos/tilray-shares-hit-new-high).
The Federal Aviation Administration (FAA) is launching a new plan to avoid flight delays in New York City and Washington, D.C. this summer. The plan will lower requirements for airlines to obtain take off and landing rights to help avoid congestion.
Lawmakers grilled TikTok CEO Shou Zi Chew on Thursday in a high-stakes hearing on the future of the popular, Chinese-owned video sharing platform in the U.S.
Actress Lindsay Lohan appears at the Christian Siriano Fall/Winter 2023 fashion show in New York, Feb. 9, 2023. The Securities and Exchange Commission said Wednesday, March 22, that Lohan, rapper Akon and several other celebrities have agreed to pay tens of thousands of dollars to settle claims that they promoted crypto investments to their millions of social media followers without disclosing they were being paid to do so.
Cheddar News breaks down what to look for on The Day Ahead, as TikTok CEO is scheduled to testify before Congress on Thursday while earnings from General Mills and Darden Restaurants are on tap. Residential sales data for February is also scheduled to be released.
Virgin Orbit is reportedly in talks for a $200 million rescue plan and the company said in a regulatory filing that it plans to resume operations on Thursday.
Jack Daniels was at the U.S. Supreme Court today. The whiskey-makers argued that a dog toy company violated federal trademark law with a product that parodies the distiller's iconic bottle. The toy is the Bad Spaniels Silly Squeaker toy by VIP products. The first amendment case pits the rights of a famous trademark holder against parody products. Jack Daniel says the toy damages its reputation, especially the references to dog poop.
Alcohol brand White Claw is moving into spirits amid an industrywide shift away from hard seltzers. The spiked seltzer brand announced a new line of regular and flavored White Claw premium vodkas. The bottles are available in select markets across North America and come in an unflavored option as well as pineapple mango and black cherry white Claw has dominated the Heart Seltzer market for years. Now bringing the category into the mainstream as more consumers sought those low calorie alcohol drinks.
